Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Amphiregulin** is an endogenous epidermal growth factor family ligand and heparin-binding protein that activates **epidermal growth factor receptor** signaling, driving cellular proliferation, differentiation, tissue repair, and fibroblast activation. In the provided public sources, amphiregulin appears both as a biologic culture supplement used in assisted reproduction and as a disease-relevant signaling molecule in fibrosis and inflammatory disorders. A registered interventional fertility study at My Duc Hospital lists amphiregulin as a drug intervention in in vitro maturation media for oocytes, indicating human interventional use in an ART setting, while peer-reviewed and meeting literature describe amphiregulin as a mediator of intestinal, pulmonary, skin, and other fibrotic or inflammatory processes. It is not an approved branded medicine and is better understood as a recombinant or exogenous form of a native human growth factor used experimentally and translationally rather than as a conventional commercial therapeutic drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amphiregulin.